These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2022 related items for PubMed ID: 8569195

  • 1. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
    Brasoveanu LI, Altomonte M, Fonsatti E, Colizzi F, Coral S, Nicotra MR, Cattarossi I, Cattelan A, Natali PG, Maio M.
    Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
    [Abstract] [Full Text] [Related]

  • 2. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ.
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [Abstract] [Full Text] [Related]

  • 3. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR, Blom DJ, de Waard-Siebinga I, van Beelen E, Claas FH, Jager MJ, Gorter A.
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
    [Abstract] [Full Text] [Related]

  • 4. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.
    Brasoveanu LI, Fonsatti E, Visintin A, Pavlovic M, Cattarossi I, Colizzi F, Gasparollo A, Coral S, Horejsi V, Altomonte M, Maio M.
    J Clin Invest; 1997 Sep 01; 100(5):1248-55. PubMed ID: 9276743
    [Abstract] [Full Text] [Related]

  • 5. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
    Mäenpää A, Junnikkala S, Hakulinen J, Timonen T, Meri S.
    Am J Pathol; 1996 Apr 01; 148(4):1139-52. PubMed ID: 8644856
    [Abstract] [Full Text] [Related]

  • 6. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA, van Wieringen PA, van Es LA, Daha MR.
    Eur J Immunol; 1992 Dec 01; 22(12):3135-40. PubMed ID: 1280224
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement.
    Coral S, Fonsatti E, Sigalotti L, De Nardo C, Visintin A, Nardi G, Colizzi F, Colombo MP, Romano G, Altomonte M, Maio M.
    J Cell Physiol; 2000 Dec 01; 185(3):317-23. PubMed ID: 11056001
    [Abstract] [Full Text] [Related]

  • 8. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
    Ravindranath NM, Shuler C.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb 01; 103(2):231-9. PubMed ID: 17234541
    [Abstract] [Full Text] [Related]

  • 9. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity.
    Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A.
    Int J Cancer; 1995 May 16; 61(4):548-56. PubMed ID: 7538980
    [Abstract] [Full Text] [Related]

  • 10. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR.
    Virology; 1994 Nov 15; 205(1):82-92. PubMed ID: 7526538
    [Abstract] [Full Text] [Related]

  • 11. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
    Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP.
    Am J Pathol; 1996 Jul 15; 149(1):129-42. PubMed ID: 8686736
    [Abstract] [Full Text] [Related]

  • 12. Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.
    De Nardo C, Fonsatti E, Sigalotti L, Calabrò L, Colizzi F, Cortini E, Coral S, Altomonte M, Maio M.
    J Cell Physiol; 2002 Feb 15; 190(2):200-6. PubMed ID: 11807824
    [Abstract] [Full Text] [Related]

  • 13. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M, Yefenof E, Klein G, Klein E.
    Eur J Immunol; 1992 Jul 15; 22(7):1871-6. PubMed ID: 1378022
    [Abstract] [Full Text] [Related]

  • 14. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells.
    Junnikkala S, Hakulinen J, Meri S.
    Eur J Immunol; 1994 Mar 15; 24(3):611-5. PubMed ID: 7510237
    [Abstract] [Full Text] [Related]

  • 15. Cell-surface expression of complement restriction factors and sialyl Lewis antigens in oral carcinoma: relevance to chemo-immunotherapy.
    Ravindranath NM, Nishimoto K, Chu K, Shuler C.
    Anticancer Res; 2000 Mar 15; 20(1A):21-6. PubMed ID: 10769630
    [Abstract] [Full Text] [Related]

  • 16. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
    Charreau B, Cassard A, Tesson L, Le Mauff B, Navenot JM, Blanchard D, Lublin D, Soulillou JP, Anegon I.
    Transplantation; 1994 Dec 15; 58(11):1222-9. PubMed ID: 7527603
    [Abstract] [Full Text] [Related]

  • 17. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.
    Fletcher A, Bryant JA, Gardner B, Judson PA, Spring FA, Parsons SF, Mallinson G, Anstee DJ.
    Immunology; 1992 Mar 15; 75(3):507-12. PubMed ID: 1374058
    [Abstract] [Full Text] [Related]

  • 18. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59.
    Clayton A, Harris CL, Court J, Mason MD, Morgan BP.
    Eur J Immunol; 2003 Feb 15; 33(2):522-31. PubMed ID: 12645951
    [Abstract] [Full Text] [Related]

  • 19. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells.
    Hakulinen J, Meri S.
    Lab Invest; 1994 Dec 15; 71(6):820-7. PubMed ID: 7528832
    [Abstract] [Full Text] [Related]

  • 20. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
    Shimo K, Mizuno M, Nasu J, Hiraoka S, Makidono C, Okazaki H, Yamamoto K, Okada H, Fujita T, Shiratori Y.
    J Gastroenterol Hepatol; 2004 Jun 15; 19(6):643-7. PubMed ID: 15151618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 102.